NICE backs ‘pioneering’ treatment for advanced breast cancer
Around 1,200 people with advanced breast cancer could benefit from a decision by NICE to give the go-ahead to a new treatment. Find out more.
Improving Treatment Access to Innovative Therapies in Breast Cancer
Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
Drug in clinical trials for breast cancer could also treat some blood cancers
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer
Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.
Innovations in Breast Cancer Treatment With Dr Dawn Klemow
Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
AstraZeneca’s Datroway approved in U.S. for HER2-negative breast cancer patients
DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo. The Anglo-Swedish drugmaker on Friday said that the approval is for adult breast cancer patients who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
Women on Medicaid at Higher Risk of Breast Cancer
Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.
Cure Today12h
Long-Term Patient Care Focuses on Precision-Based Therapy in Breast Cancer
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
Rolling Out10d
Breast cancer surgery myth shattered
A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...
Young women are almost twice as likely to be diagnosed with cancer as young men: ‘We’re seeing a change’
Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...
News Medical on MSN13d
NUS researchers boost chemotherapy uptake in breast cancer treatment with localised magnetic fields
Researchers at the National University of Singapore (NUS) have developed a non-invasive method to improve the effectiveness ...
Rolling Out10d
3 crucial breast cancer warning signs Black women must know
Discover the 3 critical warning signs of breast cancer that every Black woman should know, plus insights on early detection ...
Science Daily13d
Researchers boost chemotherapy uptake in breast cancer treatment with localized magnetic fields
Researchers have developed a non-invasive method to improve the effectiveness of chemotherapy while reducing its harmful side effects. By applying brief, localized pulses of magnetic fields, the team ...